Resumen

CANO, Clímaco et al. La Trimetazidina Disminuye la Glicemia Basal en Ratas con Hiperglicemia de Ayuno. AVFT [online]. 2000, vol.19, n.1, pp.58-61. ISSN 0798-0264.

Trimetazidine (TMZ) is a drug with cardioprotective properties used in coronary artery disease. Its effect has been attributed to inhibition of the long chain fatty acids intra-mitochondrial transport via Carnitin-Palmitoil-transferase- 1. Clinical evidence supports the possibility that TMZ is able to improve the fasting hyperglycemia in diabetic patients. For this reason, the objective of the present study was to determine the effect of TMZ on plasma glucose of Sprague-Dawley rats under fasting hyperglycaemia. All the a animals received water and food "ad libitum" and two daily TMZ doses (1 mg/Kg) during 30 days. In order to complete the study, were collected (in fasting period) two blood samples, the last day of treatment (30th day) and 15 days post-treatment and processed with the purpose of evaluate the concentration of plasma glucose. The fasting glycaemia after 30 days of TMZ administration, diminished significantly from 141,27 ± 3,31 mg/dl to 120,90 ± 5,84 mg/dl (p <0,01). Fifteen days after firnishing treatment, the fasting plasma glucose levels increased again (from 12O,90 ± 5,84 to 137,09 ± 7,08 mg/dl) (p< 0,05). These data suggest that TMZ improves glucose utilization by activation of the glucolitic pathway in muscular and hepatic cells to the disminish hyperglycaemic state in diabetic rats.

Palabras clave : Glycaemia; Trimetazidine; Hypoglycemic drugs.